A phase 2/3, multicenter, randomized, double-blind, placebo-controlled, combined dose finding and cardiovascular outcome study t

A phase 2/3, multicenter, randomized, double-blind, placebo-controlled, combined dose finding and cardiovascular outcome study to investigate the efficacy and safety of CSL300 (clazakizumab) in subjects with end stage kidney disease undergoing dialysis.

Abierta

Código protocolo: CSL300_2301
Código EudraCT: No aplica
Grupo de investigación: Nefrología y Trasplante Renal
Servicio: Nefrología
Investigador/a principal: Ramos Terrades, Natalia
Patología: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III